Phase 1 Dermatomyositis Clinical Trials
9 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–9 of 9 trials
Recruiting
Phase 1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Phase 1Phase 2
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Systemic Lupus ErythematosusDermatomyositisPolymyositis+1 more
Miltenyi Biomedicine GmbH24 enrolled1 locationNCT06347718
Recruiting
Phase 1
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Systemic Sclerosis (SSc)Polyarticular Juvenile Idiopathic ArthritisPrimary Sjogren's Syndrome+1 more
Chongqing Precision Biotech Co., Ltd11 enrolled1 locationNCT07184450
Recruiting
Phase 1
Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Dermatomyositis
Stanford University21 enrolled2 locationsNCT06298019
Recruiting
Phase 1
Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial
Anti-MDA5 Positive Dermatomyositis-Associated RP-ILDRapidly Progressive Interstitial Lung Disease
Li Shiyue10 enrolled1 locationNCT06919380
Recruiting
Phase 1
Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)
DermatomyositisDermatomyositis, Juvenile
Chongqing Precision Biotech Co., Ltd18 enrolled1 locationNCT06686524
Recruiting
Phase 1
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
Juvenile Dermatomyositis
Chongqing Precision Biotech Co., Ltd10 enrolled1 locationNCT06569472
Recruiting
Phase 1
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
DermatomyositisSystemic SclerodermaAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+2 more
Chongqing Precision Biotech Co., Ltd24 enrolled1 locationNCT06056921